Clarametyx reports progress on study of antibody therapy CMTX-101 for infections associated with CF, to begin phase 2a portion of the trial: Columbus, Ohio Saturday, October 19, 2 ...
Antibiotic resistance is a growing threat that is already thought to contribute to the deaths of millions of people every year. | Genetics And Genomics ...